melanoma
|
0.020 |
GeneticVariation
|
disease |
LHGDN |
Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma.
|
18385040 |
2008 |
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Bypass of OIS by depletion of RASEF was associated with suppression of several senescence biomarkers including senescence-associated (SA)-β-galactosidase activity, interleukins, and tumor suppressor p15(INK) (4B) .
|
24703243 |
2014 |
Uveal melanoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Many other genes might also be involved in the pathogenesis of UM such as the Ras and EF-hand domain containing (RASEF) gene, RAB31, hTERT, embryonal fyn-associated substrate, and deleted in split-hand/split-foot 1.
|
29578129 |
2018 |
Myeloid Leukemia, Chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results identify a new signaling molecule involved in BCR-ABL modulation of apoptosis and suggest that RAB45 induction strategies may have therapeutic utility in patients with CML.
|
21890458 |
2011 |
Abnormal behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Cigarette smoke extract induced HPASMCs behavioral changes and RASEF hypermethylation followed by silencing, while DNMT1 knockdown markedly inhibited these changes.
|
30845941 |
2019 |
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer.
|
23686708 |
2013 |
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
RASEF may play an important role in lung carcinogenesis and could serve as a vaiable prognostic biomarker and target for the development of new molecular therapies.
|
23686708 |
2013 |
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer.
|
23686708 |
2013 |
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer.
|
23686708 |
2013 |
Uveal melanoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
In this study, the RASEF gene was investigated for potential mutations and gene silencing by promoter methylation in uveal melanoma.
|
18385040 |
2008 |
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Low RASEF expression in the cell lines and primary tumors correlated with methylation of the RASEF promoter region.
|
18385040 |
2008 |
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Expression of RASEF, a known gene in this region, was examined in tumor tissue from 10 sporadic CMM lesions and was found to be decreased in 70% of these tumors compared with RASEF expression in a human reference RNA pool from 10 different cell types and in 10 breast tumors.
|
16174859 |
2005 |
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical staining using tumor tissue microarrays consisting of 341 archived non-small cell lung cancers (NSCLC) revealed the association of strong RASEF positivity with poor prognosis (P = 0.0034 by multivariate analysis).
|
23686708 |
2013 |
melanoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
With genome-wide DNA methylation analysis, we found one of these genes, RASEF, to be hypermethylated in primary cutaneous melanomas but not nevi.
|
24703243 |
2014 |
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Expression of RASEF, a known gene in this region, was examined in tumor tissue from 10 sporadic CMM lesions and was found to be decreased in 70% of these tumors compared with RASEF expression in a human reference RNA pool from 10 different cell types and in 10 breast tumors.
|
16174859 |
2005 |